Fulminant Immune Checkpoint Inhibitor–Associated Myocarditis Presenting with Complete Atrioventricular Block After Combined Nivolumab and Ipilimumab Therapy: An Autopsy-Confirmed Case Report

Background: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but potentially fatal immune-related adverse event that may present with conduction abnormalities, ventricular arrhythmias, cardiogenic shock, and sudden cardiac death. The risk is increased with combined programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade. We report a fatal case of fulminant ICI-associated myocarditis following combined nivolumab and ipilimumab therapy. Case Presentation: A 79-year-old man with metastatic clear-cell renal cell carcinoma developed progressive fatigue and exertional dyspnea 14 days after his first and only cycle of nivolumab and ipilimumab. Electrocardiography revealed complete atrioventricular block. High-sensitivity cardiac troponin T increased from 2575 to 11,327 pg/mL, whereas creatine kinase initially decreased from 8690 U/L before rising again. Coronary angiography excluded obstructive coronary artery disease. Temporary transvenous pacing was followed by permanent pacemaker implantation. Despite intensive care, the patient developed progressive hemodynamic deterioration requiring vasopressor support and ultimately fatal cardiorespiratory collapse. ICI-associated myocarditis was not recognized during life; therefore, no myocarditis-directed diagnostic work-up or immunosuppressive treatment was initiated. Post-mortem examination demonstrated pronounced diffuse lymphohistiocytic myocarditis involving both atria and ventricles. ICI-associated myocarditis was identified as the cause of death, with a concomitant retroperitoneal abscess with pancreatic fistulation considered an aggravating condition. Conclusions: Complete atrioventricular block accompanied by a marked dynamic troponin increase should raise suspicion of ICI-associated myocarditis, particularly after exclusion of obstructive coronary artery disease. In this case, the diagnosis was established only post mortem. Earlier recognition of this clinical constellation may facilitate timely myocarditis-directed diagnostic evaluation and treatment.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-10-28
DOI
https://doi.org/10.3390/diagnostics16213536
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fulminant Immune Checkpoint Inhibitor–Associated Myocarditis Presenting with Complete Atrioventricular Block After Combined Nivolumab and Ipilimumab Therapy: An Autopsy-Confirmed Case Report

Thomas Joseph Vogl, Boris Schmidt, Hamzah Adwan, Nihat Firat Sipahi et al.
3 links
Diagnostics
Cancer Immunotherapy and Biomarkers
article

Fulminant Immune Checkpoint Inhibitor–Associated Myocarditis Presenting with Complete Atrioventricular Block After Combined Nivolumab and Ipilimumab Therapy: An Autopsy-Confirmed Case Report

Thomas Joseph Vogl, Boris Schmidt, Hamzah Adwan, Nihat Firat Sipahi, Anton Richter, Simon Little, Araba Benyarko, Jonas Knoblich
article en

Abstract

Background: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but potentially fatal immune-related adverse event that may present with conduction abnormalities, ventricular arrhythmias, cardiogenic shock, and sudden cardiac death. The risk is increased with combined programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade. We report a fatal case of fulminant ICI-associated myocarditis following combined nivolumab and ipilimumab therapy. Case Presentation: A 79-year-old man with metastatic clear-cell renal cell carcinoma developed progressive fatigue and exertional dyspnea 14 days after his first and only cycle of nivolumab and ipilimumab. Electrocardiography revealed complete atrioventricular block. High-sensitivity cardiac troponin T increased from 2575 to 11,327 pg/mL, whereas creatine kinase initially decreased from 8690 U/L before rising again. Coronary angiography excluded obstructive coronary artery disease. Temporary transvenous pacing was followed by permanent pacemaker implantation. Despite intensive care, the patient developed progressive hemodynamic deterioration requiring vasopressor support and ultimately fatal cardiorespiratory collapse. ICI-associated myocarditis was not recognized during life; therefore, no myocarditis-directed diagnostic work-up or immunosuppressive treatment was initiated. Post-mortem examination demonstrated pronounced diffuse lymphohistiocytic myocarditis involving both atria and ventricles. ICI-associated myocarditis was identified as the cause of death, with a concomitant retroperitoneal abscess with pancreatic fistulation considered an aggravating condition. Conclusions: Complete atrioventricular block accompanied by a marked dynamic troponin increase should raise suspicion of ICI-associated myocarditis, particularly after exclusion of obstructive coronary artery disease. In this case, the diagnosis was established only post mortem. Earlier recognition of this clinical constellation may facilitate timely myocarditis-directed diagnostic evaluation and treatment.

DiagnosticsVol. 16(21)
Goethe University Frankfurt (DE), University Hospital Frankfurt (DE), Agaplesion Markus Hospital (DE)
Good health and well-being
Openalex Percentile: Top 16%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon